Sanofi (NASDAQ:SNY) Shares Acquired by Bailard Inc.

Bailard Inc. lifted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 69.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,736 shares of the company's stock after buying an additional 11,377 shares during the period. Bailard Inc.'s holdings in Sanofi were worth $1,538,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lee Danner & Bass Inc. acquired a new position in shares of Sanofi in the fourth quarter worth about $31,000. Bessemer Group Inc. raised its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the period. Golden State Wealth Management LLC raised its position in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the period. UMB Bank n.a. raised its position in shares of Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after acquiring an additional 264 shares during the period. Finally, Wayfinding Financial LLC purchased a new stake in shares of Sanofi during the first quarter worth about $63,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

SNY traded down $0.33 on Friday, hitting $48.32. 1,652,894 shares of the company traded hands, compared to its average volume of 2,318,942. The company has a 50 day moving average of $49.65 and a 200-day moving average of $52.11. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $118.50 billion, a PE ratio of 17.26, a PEG ratio of 1.10 and a beta of 0.48. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company's revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.78 EPS. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on SNY shares. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.